0 rating

Management – Complications and Comorbidities

Persson F, Rossing P, Reinhard H et al.

Steno Diabetes Center, Gentofte, Denmark.

 Diabetes Care 2009;32:1873–9.

Editor’s note: Aliskiren is the first of a new group of antihypertensive agents, the direct renin inhibitors, which act on the renin–angiotensin system at its rate-limiting step. Both angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have been shown to be useful in the management of patients with diabetes and renal disease, particularly in reducing the level of proteinuria (Kidney Int 2008;73:1419–25, N Engl J Med 2008;358:2433–46). In this study, the authors compared the effects of aliskiren as monotherapy and in combination with irbesartan in type 2 diabetes patients with hypertension and significant proteinuria.

Return to top

LATEST ARTICLES

Our most popular articles